Citations

Clear

1011 citation(s) found for "Barry, WT".

Abstract 18738: Pulmonary Artery Systolic Pressures Increase With Aging: A Longitudinal, Population Based Study
Chandra, Suparna, Redfield, Margaret M. , Karon, Barry L., Rodeheffer, Richard J. , Kane, Garvan C.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a18738 Get It

Background: A community based, cross-sectional echo survey demonstrated that pulmonary artery systolic pressure (PASP) increases with age and that PASP is associated with systemic arterial stiffness, Doppler estimated left ventricular (LV) filling pressures and lung function. Longitudinal assessment of PASP is needed to confirm cross-sectional observations. Objectives: To assess the whether PASP changes over time in longitudinally studied subjects and determine whether changes in PASP are associated with changes in systemic vascular stiffness, LV filling pressures or lung function. Methods: A random sample (n=2042) of the Olmsted County, MN population over age 40 underwent echo, record review and spirometry between 1997-2000 (Exam 1). A subset (n=1402) underwent repeat studies four years later (2001-2004; Exam 2). The current analysis includes the 723 subjects with paired PASP measurements. Changes ([[Unable to Display Character: ▵]]) in PASP, systemic arterial stiffness (pulse pressure; PP), LV filling pressure (E/e’) and lung function (% age/sex expected forced expiratory volume, %FEV1) were assessed. Results: At Exam 1, the median (interquartile range) age was 62 (69-70) years (62% female). Median time between exams was 48 (47-49) months. PASP increased from 26.1 (24.4-30.0) mmHg at Exam 1 to 28.0 (24.4-32.0) mmHg at Exam 2 (p<0.0001 by paired t test) for an average (SD) [[Unable to Display Character: ▵]] of 1.2 ± 5.5 mmHg. Adjusting for age and PASP at Exam 1, [[Unable to Display Character: ▵]]PASP was associated with [[Unable to Display Character: ▵]] age with an increase (parameter estimate (pe) ± standard error (se)) of 1.4±0.7 mmHg per year increase in age (p=0.046). [[Unable to Display Character: ▵]]PASP was not associated with sex and there was no age-sex interaction. Adjusting for age and PASP at Exam 1, [[Unable to Display Character: ▵]] age and Exam 1 values for PP, E/e or %FEV1 as appropriate, [[Unable to Display Character: ▵]]PASP was associated with [[Unable to Display Character: ▵]] PP (pe±se = 0.03±0.01 mmHg; p=0.01) [[Unable to Display Character: ▵]]E/e’ (pe±se = 0.21±0.06 mmHg, p=0.001) and [[Unable to Display Character: ▵]]%FEV1 (-0.09±0.02 mmHg, p<0.0001) suggesting that increases in PASP were related to increases in vascular stiffening, increases in LV filling pressures and declining lung function. Conclusions: In this longitudinal, population based study we find that PASP increases with aging and that increases in PASP over time are related to increases in systemic vascular stiffness and LV filling pressures and decreases in lung function.
Abstract 18524: Left Atrial Function is Associated With Cardiopulmonary Performance in Heart Failure With Preserved Ejection Fraction: A Relax Substudy
McNulty, Steven E., Neilan, Tomas G. , Haines, Phillip, Semigran, Mark J, Jerosch‐Herold, Michael , Kim, Raymond J. , Redfield, Margaret M. , Shah, Ravi V. , Abbasi, Siddique A. , Hernandez, Adrian F. , Borlaug, Barry A. , Lewis, Gregory D. , Kwong, Raymond Y.K.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a18524 Get It

Introduction: Impaired left atrial (LA) function may limit optimal cardiac performance, reflecting both LA load and atrial dysfunction in HFpEF. The link between MRI-derived LA characteristics and exercise capacity in HFpEF has not been studied. Hypothesis: We hypothesized that total LA emptying fraction (LAEF) is reduced in HFpEF vs. healthy controls and LA functional impairment would be correlated with LV diastolic dysfunction, vascular dysfunction, and exercise intolerance. As LA hypertension may increase right ventricular load and limit increases in pulmonary perfusion with exercise, the correlation of LAEF with ventilatory efficiency (VE/VCO2 slope) was also examined. Methods: Baseline exercise, echo, and cardiac MRI data from RELAX (a study of sildenafil in HFpEF) in patients in sinus rhythm with a measureable LAEF by MRI (n=100) were utilized. Healthy volunteers (n=21) were included for comparison. LAV was measured by the biplane area-length method using 2-/4-chamber SSFP CMR. LAEF was defined as total (ΔLAVmax-min), passive/conduit (ΔLAVmax-before atrial contraction ), and active (ΔLAVbefore atrial contraction-min), each divided by maximal LAV. Results: As compared to controls, LAEF (particularly passive conduit function) was reduced in HFpEF (Table 1). In HFpEF, patients with lower LAEF had a larger LA, more echo diastolic dysfunction, higher PA systolic pressure and NT-proBNP, reduced aortic distensibility, worse exercise capacity, and ventilatory inefficiency (Table 2). Conclusions: LA function is impaired in HFpEF, may serve as a marker of chronic LA hypertension and may contribute to impaired exercise intolerance and ventilatory inefficiency.
Abstract 13977: Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction
Maron, Barry J. , Ommen, Steve R. , Maron, Martin S. , Ralph‐Edwards, Anthony, Balaram, Sandhya K. , Rastegar, Hassan , Rowin, Ethan J. , Smedira, Nicholas G. , Lytle, Bruce W. , Desai, Milind Y. , Lever, Harry M., Dearani, Joseph A. , Schaff, Hartzell V. , Nishimura, Rick A. , Sherrid, Mark V. , Swistel, Daniel G.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13977 Get It

Background: Treatment of progressive heart failure, due to left ventricular (LV) outflow tract obstruction has been a major component of hypertrophic cardiomyopathy (HCM) disease management for 50 years. Septal myectomy has been the primary treatment option to abolish gradients and relieve heart failure symptoms. The role of myectomy in HCM management has depended on effectiveness in relieving heart failure symptoms, but also an acceptable operative risk. Methods: Over the most recent 15-year period, we reviewed 3,700 consecutive isolated myectomy operations performed at major North American HCM institutions. Composite operative mortality (first 30 days) was only 0.4%. Seventeen operative deaths were at ages 24 to 82 (≥70 years), and only 6 occurred after 2010. Notably, 2 of the 4 Mayo Clinic deaths were in patients with prior alcohol septal ablation. Septal myectomy, when performed in experienced HCM centers, was much safer when compared to operative mortality with coronary artery bypass grafting (2.3%); valve replacement (3.5%); mitral valve replacement specifically (5.7%) (STS Database), similar to atrial or ventricular septal defect closure and 15-fold less than myectomy in community hospital or low volume surgical settings. Conclusions: Surgical myectomy performed in dedicated HCM centers with experienced surgeons and staff is one of the safest open-heart procedures currently practiced, with a mortality rate as low as 0.4%. The large mortality discrepancy for myectomy between community hospitals and dedicated HCM centers underscores that this operation should be considered a specialized procedure best performed in high volume HCM institutions.
Abstract 13545: ST2 in Heart Failure With Preserved Ejection Fraction
Stevens, Susanna R., Chen, Horng H. , Redfield, Margaret M. , AbouEzzeddine, Omar F. , McKie, Paul M. , Dunlay, Shannon M. , Felker, G. Michael , Borlaug, Barry A. , Tracy, Russell P. , Braunwald, Eugene

Mayo Clinic

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.13545 Get It

Introduction: In vitro, ST2 is a marker of myocyte stress and inflammation but in vivo, there is no trans-cardiac ST2 concentration step-up to support cardiac ST2 activation in human heart failure (HF) calling into question the source of ST2 in HF. While ST2 is predictive of adverse outcomes in HF, the relationship between ST2 and key pathophysiologic domains in HF with preserved ejection fraction (HFpEF) is not well characterized. Hypothesis: ST2 levels increase in proportion to the severity of left ventricular (LV) remodeling and dysfunction in HFpEF. Methods: At enrollment, patients (n=174) from the RELAX trial testing sildenafil in HFpEF had serum ST2 levels measured and underwent assessment of pathophysiologic domains including congestion, cardiac structure and function, exercise performance (peak oxygen consumption (VO2)) and biomarkers of neurohumoral activation (NT-proBNP, aldosterone, endothelin-1), renal dysfunction (cystatin-C), fibrosis (pro-collagen III N-terminal peptide [NTP], C-telopeptide for type I collagen [CITP]), inflammation (high-sensitivity CRP [hsCRP]) and myocardial necrosis (high-sensitivity troponin-I [hsTnI]). Analysis adjusted for sex, a covariate associated with ST2 levels in normal persons. Results: See table. ST2 was associated with greater congestion, worse right ventricular (RV) pressure overload and dysfunction, lower peak VO2 and biomarkers of neurohumoral activation, renal dysfunction, fibrosis and myocardial necrosis and tended to be associated with systemic inflammation (hsCRP). ST2 was not associated with LV structure or LV systolic or diastolic function. Conclusions: In HFpEF, ST2 was associated with measures of right sided congestion, RV overload and dysfunction, exercise intolerance and other systemic markers of more advanced HF but not with LV structure or LV systolic or diastolic function. These data suggest that mechanisms distinct from LV stress stimulate ST2 activation in HFpEF.
Understanding Patients’ Current Acceptability of Artificial Intelligence During Colonoscopy for Polyp Detection: A Single Center Study
Schmidt, K., Barry, Brenda J. , Schmidt, K., Sood, S., Dilmaghani, Saam , Goyal, M., Barry, B., Zhu, Xin , Coelho–Prabhu, Nayantara

Mayo Clinic

Endoscopy | April 23, 2024 | Volume: 56 | Issue: S 02 | Pages: S175-S176

10.1055/s-0044-1783083 Get It

Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Park, Han-Sol , Yin, Anna , Barranta, Caelan, Caputo, Christopher , Sachithanandham, Jaiprasath , Li, Maggie , Yoon, Steve, Sitaras, Ioannis , Jedlicka, Anne , Eby, Yolanda , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Spivak, Emily S , Huamán, Moisés A. , Blair, Janis E. , Gerber, Jonathan M. , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Marshall, Christi E., Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Singh, Atika, Jabs, Douglas A. , Shade, David , Lau, Bryan , Ehrhardt, Stephan , Baksh, Sheriza , Ou, Jiangda , Na, Yu Bin , Knoll, Maria Deloria , Ornelas-Gatdula, Elysse, Gniadek, Thomas J. , Wu, Jinke, Ndahiro, Nelson , Betenbaugh, Michael J. , Ziman, Alyssa , Bloch, Evan M. , Laeyendecker, Oliver , Ziman, Alyssa , Huaman, Moises A , Laeyendecker, Oliver , Lee, John S. , Shenoy, Aarthi , Mosnaim, Giselle S , Levine, Adam C , Meisenberg, Barry R. , Anjan, Shweta , Currier, Judith S. , Paxton, James H , Sutcliffe, Catherine G , Zand, Martin S. , Raval, Jay S. , Kassaye, Seble , Yarava, Anusha , Ford, Daniel E , Appel, Lawrence J. , Shapiro, Janna R. , Arroyo‐Currás, Netzahualcóyotl , Caturegli, Patrizio , Hanley, Daniel F. , Casadevall, Arturo , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Pekosz, Andrew , Klein, Sabra L , Sullivan, David

Mayo Clinic

JCI Insight | April 23, 2024 | Volume: 9 | Issue: 8 | Pages: No page available

10.1172/jci.insight.178460 | PMID 38483534 Get It

BACKGROUND COVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined. METHODS This secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization–equivalent anti–Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis. RESULTS SARS-CoV-2 anti–S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01). CONCLUSION In unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors’ antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use. TRIAL REGISTRATION ClinicalTrials.gov NCT04373460. FUNDING Department of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation.
Abstract 19659: Long Term Left Ventricular Assist Device Therapy: Renal Response to Pulsatile vs Continuous Flow
Sajgalik, Pavol , J, Park Soon, Edwards, Brooks S., Kuswaha, Sudrih, Daly, Richard C. , Joyce, Lyle D., Nemec, Peter, Kára, Tomáš, Brunett, John C, Boilson, Barry A. , Chen, Horng H. , Schirger, John A.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 126 | Issue: suppl_21 | Pages: No page available

10.1161/circ.126.suppl_21.a19659 Get It

Background: Left ventricle assist device (LVAD) support, a well established therapy in advanced CHF, improves renal function assessed by creatinine. While renal function in large numbers of continuous flow (CF) LVADs vs pulsatile flow (PF) LVADs has been evaluated at 3 mo., long term studies are needed with large numbers of CF vs PF devices. To date longer term analysis comparing renal function in CF vs PF devices have relied on a small number of CF devices. We evaluated renal function assessed by creatinine in a large number of CF (HM II) (n=119) devices and compared this to renal function in a group of subjects treated with PF devices (HM XVE) (n=8) at 6 mo. post implant. Our aim was to evaluate change in creatinine between 3 and 6 months in these groups. Methods and Results: Plasma creatinine was evaluated at 3 and 6 months in two groups: subjects with CF HM II (n=119) and PF LVAD (HM XVE, n=8). The data were collected from two centers in patients undergoing implant for destination or bridge to transplant therapy. Baseline creatinine was higher in the HM XVE group at baseline (BL), and decreased at 3 mo. (1.7 [1.1-2.1] vs 1.1 [0.8-1.5] mg/dL, p<0.05). BL creatine in the HM II group decreased at 3 mo as well (1.2 [1-1.5] vs 1.1 [0.9-1.3] mg/dL, p,0.05). Between 3 and 6 months there was no difference in degree of creatinine change in CF vs PF, however both groups had an increase in Creatinine in this time frame: PF (1.1 [0.8-1.5] vs 1.35 [1.05-1.9] mg/dL, p<0.05); CF (1.1 [0.9-1.3] vs 1.2 [0.92-1.4] mg/dL, p<0.05). Conclusion: This is the first study to demonstrate with large numbers of CF LVAD that creatinine does not incrementally increase between 3 and 6 mo. in comparison to PF LVAD. Further studies are required with large numbers of continuos flow LVADs evaluating the comparative effect of long term continuous flow vs pulsatile flow. Additionally, it remains important to identify surrogates of pulsatility in subjects with continuous flow devices and evaluate prognostic impact on renal function long term.
Abstract 18156: Donor Specific Alloantibodies to HLA II Antigens Result in Accelerated Cardiac Allograft Vasculopathy Assessed by 3d Volumetric Ivus
Topilsky, Yan , Hasin, Tal , Raichlin, Eugenia , Boilson, Barry A. , Schirger, John A., Edwards, Brooks S., Clavell, Alfredo L. , Rodeheffer, Richard J. , Joyce, Lyle D., Park, Soon J, Daly, Richard C. , Kushwaha, Sudhir S. , Pereira, Naveen L. , Gandhi, Manish J. , Frantz, Robert P. , Lerman, Amir

Mayo Clinic

Circulation | April 23, 2024 | Volume: 124 | Issue: suppl_21 | Pages: No page available

10.1161/circ.124.suppl_21.a18156 Get It

BACKGROUND: The immunologic risk associated with preformed donor-specific allo-antibodies (DSA) against human leukocyte antigens (HLA) in heart transplant (HTX) recipients is unclear. The goal of this study was to evaluate potential role of DSA on the progression of cardiac allograft vasculopathy (CAV) in HTX recipients. METHODS: The presence of DSA against HLA was evaluated using solid phase Single Antigen Bead assay (One Lambda, Inc., Canoga Park, CA; Luminex platform) before transplant in 35 HTX recipients. Using alloantibody specification analysis, 11% (4/35) and 20% (7/35) had DSA against donor Class I and II HLA respectively including the one patient who had both (DSA I & II+) . 71% (25/35) of patients had no demonstrable DSA (DSA-). All patients had negative cytotoxicity cross match. Baseline three-dimensional intravascular ultrasound studies (3D IVUS) were performed at 1.0 [0.18, 1.4] year after transplant. Follow up 3D IVUS exams were performed 0.92 [0.85, 1.04] years after the baseline exam. RESULTS: The increase in mean plaque (media and intima) volume (PV) was accelerated in the DSA II+ group as compared to the DSA- group (0.87±1.9 mm (3)/mm vs. 0.16±1.8 mm (3)/mm) but the vessel volume index (follow up vessel volume/ baseline vessel volume) was similar between groups (1.08±0.5 vs. 1.09± 0.4; p=0.9). Plaque index (PI) (PV/vessel volume x 100 [%]) increased significantly in the DSA II+ group (17.9±6.3%) but not in the DSA- group (-13.6±13.2%, P=0.02). None of these values were significant in the DSA I+ only group. Treatment with Sirolimus did not affect PI progression between the DSA II+ and DSA- groups (PI progression: 15.9±8.7% vs. -11.7±7.1%, P=0.03). Age, gender, lipid and uric acid levels, prevalence of diabetes, ischemic time, time between IVUS examinations, the use of steroids, mycophenolate vs. azathioprine or calcineurin inhibitors vs. sirolimus were not different between the groups (P>0.4 for all). CONCLUSIONS: Heart transplant recipients with clearly defined anti-Class II DSA are at risk for accelerated cardiac allograft vasculopathy. Whether interventions to minimize the risk of DSA such as virtual crossmatch, desensitization and complement inhibition will retard CAV remains to be proven.
Cell competition drives bronchiolization and pulmonary fibrosis.
Klinkhammer, Kylie , Lyu, Handeng, Yao, Changfu , Stripp, Barry R. , Warren, Rachel , Yao, Changfu , Stripp, Barry , De Langhe, Stijn P

Mayo Clinic

No container title available | April 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4177351/v1 | PMID 38746309 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease arising from the maladaptive differentiation of lung stem cells into bronchial epithelial cells rather than into alveolar type 1 (AT1) cells, which are responsible for gas exchange. Here, we report that healthy lungs maintain their stem cells through tonic Hippo and β-catenin signaling, which promote Yap/Taz degradation and allow for low level expression of the Wnt target gene Myc. Inactivation of upstream activators of the Hippo pathway in lung stem cells inhibits this tonic β-catenin signaling and Myc expression and promotes their Taz mediated differentiation into AT1 cells. Vice versa, increased Myc in collaboration with Yap promotes the differentiation of lung stem cells along the basal and myoepithelial like lineages allowing them to invade and bronchiolize the lung parenchyma in a process reminiscent of submucosal gland development. Our findings indicate that stem cells exhibiting the highest Myc levels become supercompetitors that drive remodeling, whereas loser cells with lower Myc levels terminally differentiate into AT1 cells.
A Roadmap for Therapeutic Discovery in Pulmonary Hypertension Associated with Left Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function
Pollesello, Piero , Anker, Markus S. , Backs, Johannes , Bayés‐Genís, Antoni , González, Aránzazu , Maack, Cristoph, Madden, Brendan , Redfield, Margaret M. , Rich, Stuart , Schiattarella, Gabriele G. , Skaara, Hall, Stellos, Konstantinos , Vachiéry, Jean Luc, Meer, Peter van der, Linthout, Sophie Van , Pruszczyk, Piotr , Seferović, Petar , Metra, Marco , Rosano, Giuseppe, Tocchetti, Carlo G. , Schiattarella, Gabriele G. , Stellos, Konstantinos , Metra, Marco , Tocchetti, Carlo Gabriele , Ameri, Pietro , Mercurio, Valentina , Borlaug, Barry A. , Burkhoff, Daniel , Caravita, Sergio , Chan, Stephen Y. , Man, Frances S. de , Giannakoulas, George , Guazzi, Marco , Hassoun, Paul M. , Hemnes, Anna R. , Melenovský, Vojtěch , Müller, Oliver Josef , Papp, Zoltán , Pullamsetti, Soni Savai , Rainer, Peter P. , Tedford, Ryan J. , Thum, Thomas , Vachiéry, Jean‐Luc , Meer, Peter van der , Coats, Andrew J.S. , Rosenkranz, Stephan

Mayo Clinic

European Journal of Heart Failure | April 19, 2024 | Volume: 26 | Issue: 4 | Pages: 707-729

10.1002/ejhf.3236 | PMID 38639017 Get It

Abstract Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.